Verad reports positive Phase 2 topline for oral VDPHL01 in female pattern hair loss

Verad reported positive topline Phase 2 results for VDPHL01 in females, showing robust hair growth and a favorable safety profile at Month 6.

Key Highlights:

• Study 207 (Phase 2 open-label) in females: mean non-vellus hair count increases of 22.7 (QD) and 23.3 (BID) hairs/cm² at Month 6.
• High patient-reported benefit: 88.9% (QD) and 90.0% (BID) rated ‘improved’ or ‘much improved’ on AAIRS at Month 6.
• Rapid onset: investigators saw improvement in 67.2% and 63.2% of patients reported improvement by Month 2.
• Safety: generally well tolerated through Month 6 with no treatment-related serious adverse events and no cardiac AESIs; most common AEs were hypertrichosis and peripheral edema.
• Program milestone: Company expects topline results from Phase 2/3 Study 306 in females in 1H 2027, supporting potential registrational path.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.